- Home
- NWBI vs AUPH Comparison
NWBI vs AUPH Comparison
Compare NWBI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWBI | AUPH |
|---|---|---|
| Founded | 1896 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | NWBI | AUPH |
|---|---|---|
| Price | $13.01 | $15.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $14.00 | ★ $17.25 |
| AVG Volume (30 Days) | 753.7K | ★ 949.5K |
| Earning Date | 01-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.19% | N/A |
| EPS Growth | ★ 13.78 | N/A |
| EPS | ★ 0.86 | 0.55 |
| Revenue | ★ $564,562,000.00 | $265,808,000.00 |
| Revenue This Year | $7.94 | $21.76 |
| Revenue Next Year | $8.90 | $16.45 |
| P/E Ratio | ★ $14.96 | $26.87 |
| Revenue Growth | 15.71 | ★ 20.62 |
| 52 Week Low | $10.75 | $6.55 |
| 52 Week High | $13.62 | $16.54 |
Technical Indicators
Market Signals| Indicator | NWBI | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 45.07 |
| Support Level | $12.13 | $14.36 |
| Resistance Level | $12.46 | $15.28 |
| Average True Range (ATR) | 0.29 | 0.53 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 95.94 | 36.64 |
Price Performance
Historical ComparisonAbout NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.